Program
Anti-EGFR Antibody-PI3K/PIKK Inhibitor Conjugate HMPL-A580
Its studies are led by HUTCHMED.
Furthest: phase 2, since Feb 1, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HUTCHMED | 11 open or running | phase 2since Feb 1, 2026 | Feb 1, 2026 | Dec 31, 2028phase 2 · NCT07396584 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 1, 2026First study: phase 2 study in Solid Tumors, AdultFirst studyNCT07396584 · 186 planned · United States, China
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Solid Tumors, AdultNCT07396584
TargetBeta
EGFR →read by rule
“An antibody-targeted therapy conjugate (ATTC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the receptor tyrosine kinase human epidermal growth factor receptor (EGFR) ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07396584Solid Tumors, Adult · United States, China | 2 | Recruiting | Dec 31, 2028 | 186 |
How it is read
Names in the registry
- “HMPL-A580”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.